Systems biology of cisplatin resistance: past, present and future

The platinum derivative cis-diamminedichloroplatinum(II), best known as cisplatin, is currently employed for the clinical management of patients affected by testicular, ovarian, head and neck, colorectal, bladder and lung cancers. For a long time, the antineoplastic effects of cisplatin have been fully ascribed to its ability to generate unrepairable DNA lesions, hence inducing either a permanent proliferative arrest known as cellular senescence or the mitochondrial pathway of apoptosis. Accumulating evidence now suggests that the cytostatic and cytotoxic activity of cisplatin involves both a nuclear and a cytoplasmic component. Despite the unresolved issues regarding its mechanism of action, the…

• AP
  Association pour la Recherche sur le Cancer
• EC
  European Commission
• AN
  Agence Nationale de la Recherche
• LC
  Ligue Contre le Cancer
• FD
  Fondation de France
• AI
  Associazione Italiana per la Ricerca sul Cancro
• IN
  Institut National Du Cancer
• LD
  Laboratoire d'Excellence en Recherche sur le Médicament et l'Innovation Thérapeutique
• LI
  Labex Immuno-Oncology